A Glimpse Into The Expert Outlook On AbbVie Through 7 Analysts
Portfolio Pulse from Benzinga Insights
7 analysts have recently evaluated AbbVie (NYSE:ABBV), with a mix of bullish and somewhat bullish ratings. The average 12-month price target is $190.29, slightly lower than the previous average of $193.00. Analysts have maintained or adjusted their ratings and price targets based on recent market conditions and company performance.
July 02, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have mixed views on AbbVie, with a majority being somewhat bullish. The average 12-month price target is $190.29, slightly lower than the previous average of $193.00. Recent ratings include both maintained and adjusted targets, reflecting varied expectations.
The mixed analyst ratings and slight decrease in the average price target suggest a neutral short-term impact on AbbVie's stock price. While some analysts are bullish, the overall sentiment is somewhat cautious.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100